Structured Immunity to evaluate specificity and recognition properties of a lead T cell receptor using structural immunology platform

Promising growth and recent breakthroughs have accelerated investment into the T-cell therapy industry targeting many types of cancer. New capital investment continues to fund innovative biotech firms with steady clinical trial progress and positive outcomes for many cancer patients.